Evidence map›Paper›PMID 23111904›Full record

Trial reportHepatology (Baltimore, Md.)2013

A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users.

Arthur Y Kim, Ellen H Nagami, Christopher E Birch, Melinda J Bowen, Georg M Lauer, Barbara H McGovern

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Hepatology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Article
  5. HIPPOCRATESWorld journal of hepatology · 2020
    Article
  6. Article
  7. Review
  8. Review
  9. Expert opinion on the management of hepatitis C infection in Kuwait.Hepatic medicine : evidence and research · 2018
    Article
  10. Review
  11. Article
  12. Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system.Journal of urban health : bulletin of the New York Academy of Medicine · 2015
    Article
  13. Review
  14. Article
  15. Case-finding for hepatitis C in primary care: a mixed-methods service evaluation.The British journal of general practice : the journal of the Royal College of General Practitioners · 2014
    Article
  16. Ending hepatitis C in the United States: the role of screening.Hepatic medicine : evidence and research · 2014
    Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Arthur Y KimDivision of Infectious Diseases, Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Harvard University Center for AIDS Research, Boston, MA 02114, USA. akim1@partners.org
Ellen H Nagami
Christopher E Birch
Melinda J Bowen
Georg M Lauer
Barbara H McGovern
Johns Hopkins University Center for AIDS ResearchLemuel Shattuck Hospital · USMassachusetts General Hospital · USRagon Institute of MGH, MIT and Harvard · USUniversity of Massachusetts Chan Medical School · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, ARTHUR Y · 2005 to 2014
$8.5M
Cell-mediated Immunity to HCV in HIV+ PersonsK23AI054379 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, ARTHUR Y · 2003 to 2007
$649k
NIAID NIH HHS K23 AI054379NIAID NIH HHS P30 AI060354NIAID NIH HHS U19 AI066345
6 · The paper itself

Abstract

unlabelledAcute hepatitis C virus (HCV) infection is underdiagnosed because most patients are asymptomatic. The majority of new infections occur among people who inject drugs (PWID), many of whom have a history of incarceration. In a previous pilot study, we identified symptomatic HCV cases, mainly among Caucasian inmates. We designed a cross-sectional study to evaluate whether risk factor-based screening of newly incarcerated inmates would enhance identification of asymptomatic acute HCV infection and elucidate any demographic shifts in HCV acquisition. From October 2006 to March 2008, 6,342 inmates underwent health assessments and 3,470 inmates (55%) were screened. The racial distribution was as follows: African American, 24.0%; Caucasian, 49.5%; Hispanic, 22.2%. One hundred seventy-one inmates (4.9%) were classified as high-risk. After further evaluation, 35 (20.5%) inmates were diagnosed with acute HCV with a mean age of 29 years; 62.9% were female and 91% were Caucasian. No African Americans were diagnosed with acute HCV. Our case-finding rate was 1.9 patients/month nearly a three-fold increase compared with our historical control period with a higher proportion of asymptomatic cases. We estimate a prevalence of ∼1.0% (95% confidence interval, 0.7%-1.4%) of acute HCV infections among newly incarcerated inmates.

conclusionWithin the correctional system, systematic screening based on risk factors successfully identifies acute HCV infection among PWID, including asymptomatic patients. Our data also reflect changing nationwide patterns of injection drug use that vary by age, ethnicity, and race, leading to a marked reduction of acute HCV infections among African Americans compared with non-Hispanic whites. The nationwide implementation of this simple low-cost strategy in prison-based settings could identify more than 7,000 acute HCV infections among PWID, provide insight into changing epidemiologic trends, and facilitate appropriate therapeutic and preventive interventions.

Indexed as

Acute DiseaseAdultCross-Sectional StudiesDrug UsersFemaleHepacivirusHepatitis CHepatitis C AntibodiesHumansMaleMass ScreeningMiddle AgedPilot ProjectsPrisonersProgram EvaluationRisk FactorsHepatitis C Antibodies

Identifiers

PMID23111904
PMCPMC3712277
OpenAlexW1989751527

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.